SCHEDULE 13G Filed 2026-09-08 Event — SEC 0001104659-26-105941 →

ADAR1 Capital Management, LLC → Tenax Therapeutics, Inc. TENX

Stake: — Shares: — Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

2 transactions

0 buys · 0 sales · 2 awards/exercises

Issuer Cluster

15 13D/G filings on this issuer

14 other filings besides this one

Filer Track Record

14 filings by this filer

13 other filings in the data moat

Short Interest · settle 2026-08-31

DTC 1.12

9,276,905 shares short · +69.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $5.16M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-13	Giordano Christopher Thomas	director, officer	Option exercise	219	$3.55	$777
2026-07-13	Giordano Christopher Thomas	director, officer	Option exercise	8,500	$5.94	$50K

Other 13D/G Filings on Tenax Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-08-27	SCHEDULE 13G	SPHERA FUNDS MANAGEMENT LTD.	—	—	view →
2026-08-27	SCHEDULE 13G	ING GROEP NV	—	—	view →
2026-08-18	SCHEDULE 13G	MILLENNIUM MANAGEMENT LLC	—	—	view →
2026-07-31	SCHEDULE 13D/A	Giordano Christopher Thomas	4.32%	1,690,606	view →
2026-07-08	SCHEDULE 13G	FMR LLC	—	—	view →
2026-05-20	SCHEDULE 13G	MILLENNIUM MANAGEMENT LLC	—	—	view →
2023-01-06	SC	Doogan Declan	—	—	view →
2022-09-23	SC	Rich Stuart	—	—	view →
2022-08-12	SC	Doogan Declan	—	—	view →
2022-05-20	SC	ARMISTICE CAPITAL, LLC	—	—	view →
2021-12-06	SC	Rich Stuart	—	—	view →
2021-07-09	SC	ARMISTICE CAPITAL, LLC	—	—	view →
2020-06-02	SC	Binsalamah Ziyad	—	—	view →
2018-01-04	SC	SABBY MANAGEMENT, LLC	—	—	view →

Other Filings by ADAR1 Capital Management, LLC

Filed	Form	Issuer	Stake	Shares
2026-08-14	SCHEDULE 13G	Cyclerion Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Rein Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Yarrow Bioscience, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	NextCure, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Editas Medicine, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	JATT II Acquisition Corp.	—	—	view →
2026-08-14	SCHEDULE 13G	Amanat Acquisition Corp.	—	—	view →
2026-08-14	SCHEDULE 13G	Boundless Bio, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Pliant Therapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13G	Research Alliance Corporation III	—	—	view →
2026-06-05	SCHEDULE 13G	InMed Pharmaceuticals, Inc. INM	—	—	view →
2026-06-05	SCHEDULE 13G	Rallybio Corporation RLYB	—	—	view →
2025-04-28	SCHEDULE	Keros Therapeutics, Inc. KROS	13.29%	5,390,964	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →